Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $35.85.

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price on the stock. Sanford C. Bernstein reaffirmed a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. B. Riley Financial lifted their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Wall Street Zen upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP boosted its holdings in Denali Therapeutics by 256.5% in the second quarter. Engineers Gate Manager LP now owns 57,430 shares of the company’s stock valued at $1,477,000 after purchasing an additional 41,320 shares during the period. Integrated Wealth Concepts LLC raised its position in Denali Therapeutics by 2.7% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 102,241 shares of the company’s stock valued at $2,630,000 after purchasing an additional 2,687 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Denali Therapeutics by 555.0% in the 2nd quarter. Allworth Financial LP now owns 1,834 shares of the company’s stock valued at $47,000 after buying an additional 1,554 shares during the period. Nykredit A S purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $38,000. Finally, Corient Private Wealth LP acquired a new position in shares of Denali Therapeutics during the second quarter worth about $301,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

DNLI opened at $20.53 on Friday. The firm’s fifty day simple moving average is $22.91 and its two-hundred day simple moving average is $21.88. Denali Therapeutics has a 52-week low of $13.75 and a 52-week high of $27.30. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -7.23 and a beta of 1.02. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the previous year, the business posted ($0.72) EPS. Equities analysts anticipate that Denali Therapeutics will post -2.67 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders.

Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain.